Home > Healthcare & Medical Devices > Point of Care (PoC) Molecular Diagnostics Market
Point of Care Molecular Diagnostics Market size valued at USD 3 billion in 2020 and is expected to witness 5.4% CAGR from 2021 to 2027. Growing incidence of infectious diseases has considerably driven the demand for effective diagnosis. Increasing demand for diagnostic tools to control and eliminate infectious diseases, timely detection of causative agent, allowing effective treatment and disease control will fuel the market during the forecast period. Additionally, modern techniques are enabling a remarkable makeover in the field of molecular diagnosis.
Get more details on this report - Request Free Sample PDF
Point of care molecular testing enables physicians to improve the standard of care by combining quick diagnosis with treatment decision in the first visit by the patient to have the test results. This is critical in detecting infectious agents, in determining a patient's ability to metabolize a drug or drug class, and in detecting minimal residual disease.
Report Coverage | Details |
---|---|
Base Year: | 2020 |
Market Size in 2020: | USD 3.3 Billion |
Forecast Period: | 2021 to 2027 |
Forecast Period 2021 to 2027 CAGR: | 5.4% |
2027 Value Projection: | USD 5.0 Billion |
Historical Data for: | 2016 to 2020 |
No. of Pages: | 165 |
Tables, Charts & Figures: | 175 |
Segments covered: | Technology, Application, End-use and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Get more details on this report - Request Free Sample PDF
Point of care molecular diagnostics has improved the standard of care owing to quick analysis and low cost per test. Adoption and miniaturization of current technology has also escalated its demand, thus augmenting the market growth in the coming years. Moreover, rising funding from government organizations and private firms for research and development activities will boost the market potential during the forecast timeframe.
COVID-19 has affected millions of people resulting into high infectivity and mortality rate. Quick diagnosis of COVID-19 is essential to control the spread of infectious disease. Point of care molecular diagnostics has played a vital role during pandemic from collecting samples at the right time and from the exact anatomical site that is crucial for proper diagnosis. For instance, China formulated RT-PCR as a primary diagnostic procedure for detecting SARS-CoV-2. Various major market players are collaborating with government organizations to develop products that have a potential to lower the burden of diagnosis on the primary diagnostic techniques like RT-PCR. However, concerns associated long product development time and complex regulatory process can moderately affect the industry growth during the forecast timeline.
PCR segment dominated more than 58% of the market share in 2020 led by the expansion of its application and increased precision and accuracy. In addition, RT-PCR and DNA/RNA purification are observing high growth due to their benefits such as low reagent consumption, real-time process monitoring, automation of workflow, and greater precision and reproducibility. Thus, rising occurrence of genetic disorders and infectious diseases coupled with increasing public-private investments, grants and funds for PCR-based research will further support the business growth.
Get more details on this report - Request Free Sample PDF
Infectious diseases segment in the point of care molecular diagnostics market accounted for USD 2 billion in 2020. Rising laboratory capacity for the diagnosis of infectious diseases and early detection of emerging pandemic strains will spur the industry expansion.
Growing prevalence of infectious disease in elderly people, new-born babies, and people with certain chronic illnesses coupled will impel the growth during analysis period. Additionally, increasing availability of rapid tests resulting in rising applications in faster disease diagnosis will impact the product demand in future.
Flu segment will showcase robust growth during forecast period. As per WHO, the average worldwide burden of seasonal influenza is approximately 600 million cases, with 250,000-500,000 deaths and 3 million cases of severe sickness per year. According to CDC estimates, in the U.S. about 200,000 individuals are hospitalized and around 36,000 people die from flu and its complications every year. Thus, growing disease pervasiveness and innovation in diagnostic tools will drive the segment revenue.
Hospital segment in the point of care molecular diagnostics market exceeded USD 1.50 billion revenue in 2020 propelled by sophisticated infrastructure, presence of skilled workforce and increasing number of hospital admissions. Furthermore, requirement of faster diagnostic kits in hospitals for better treatment option will further enhance the segment demand during the forecast period.
Get more details on this report - Request Free Sample PDF
North America point of care molecular diagnostics market size was over USD 1.4 billion in 2020. Rising prevalence of infectious diseases and growing application of POC tests for safe and early diagnosis will increase the demand for such rapid tests. Also, high research and development investment by governments and major market players for development of POC molecular diagnostic tests will foster the market revenue during the forecast timeline.
Increasing cases of COVID-19 in the region will boost the usage of point of care molecular diagnostic kits to manage the disease efficiently. Moreover, surmounting use of PCR-based procedures for diagnosis and commercialization of real-time PCR products will further influence the regional demand.
Some of the leading industry participants operating in the point of care molecular diagnostic market include Roche, Danaher and Abbott Laboratories. These industry players are adopting various inorganic growth strategies to obtain competitive advantage and strengthen their market position.
Market, By Technology
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: